

Active substances set

Search phrase: pazopanib

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

Kidney cancer

Pazopanib

Pazopanib is indicated in adults for the first-line treatment of advanced renal cell carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease.



**REIMBURSEMENT
WITH RESTRICTIONS**



ESMO